TWI481606B - 二苯基吡唑并吡啶衍生物、其製備及其治療用途 - Google Patents
二苯基吡唑并吡啶衍生物、其製備及其治療用途 Download PDFInfo
- Publication number
- TWI481606B TWI481606B TW099142230A TW99142230A TWI481606B TW I481606 B TWI481606 B TW I481606B TW 099142230 A TW099142230 A TW 099142230A TW 99142230 A TW99142230 A TW 99142230A TW I481606 B TWI481606 B TW I481606B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- pyrazolo
- pyridin
- compound
- fluorophenyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 230000001225 therapeutic effect Effects 0.000 title description 4
- PIWSKNFAGSZLBM-UHFFFAOYSA-N 3,5-diphenyl-1h-pyrazolo[4,3-b]pyridine Chemical class C1=CC=CC=C1C1=NNC2=CC=C(C=3C=CC=CC=3)N=C12 PIWSKNFAGSZLBM-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 122
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 85
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 41
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052801 chlorine Chemical group 0.000 claims description 17
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- -1 cyano, hydroxy Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052731 fluorine Chemical group 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 3
- 229940095102 methyl benzoate Drugs 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 94
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 239000002609 medium Substances 0.000 description 61
- 239000000203 mixture Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 29
- 239000000843 powder Substances 0.000 description 29
- 239000012074 organic phase Substances 0.000 description 28
- 239000007788 liquid Substances 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 229910000420 cerium oxide Inorganic materials 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 230000002209 hydrophobic effect Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- JFBMFWHEXBLFCR-UHFFFAOYSA-N 4-bromo-2-methylpyridine Chemical compound CC1=CC(Br)=CC=N1 JFBMFWHEXBLFCR-UHFFFAOYSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical class [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XHPJXWKQKAHNEZ-UHFFFAOYSA-N 2-(4-bromopyridin-2-yl)-1-(4-chlorophenyl)ethanone Chemical compound C1=CC(Cl)=CC=C1C(=O)CC1=CC(Br)=CC=N1 XHPJXWKQKAHNEZ-UHFFFAOYSA-N 0.000 description 2
- CNWGTEGGSUKLRZ-UHFFFAOYSA-N 2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1=CC(Br)=CC=N1 CNWGTEGGSUKLRZ-UHFFFAOYSA-N 0.000 description 2
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- VWRQZMSSWYCZTG-UHFFFAOYSA-N CC1(C(N(N(C=CC1)C)C)(C)C)C.[Li] Chemical compound CC1(C(N(N(C=CC1)C)C)(C)C)C.[Li] VWRQZMSSWYCZTG-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001638 boron Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 229960002089 ferrous chloride Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IASXNUJRNJGUPH-UHFFFAOYSA-N n-[2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethylidene]hydroxylamine Chemical compound C=1C=C(F)C=CC=1C(=NO)CC1=CC(Br)=CC=N1 IASXNUJRNJGUPH-UHFFFAOYSA-N 0.000 description 2
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BJGKVCKGUBYULR-UHFFFAOYSA-N 3-bromo-2-methylbenzoic acid Chemical compound CC1=C(Br)C=CC=C1C(O)=O BJGKVCKGUBYULR-UHFFFAOYSA-N 0.000 description 1
- PEQJGPLAMMRABH-UHFFFAOYSA-N 3-bromo-n,2-dimethylbenzamide Chemical compound CNC(=O)C1=CC=CC(Br)=C1C PEQJGPLAMMRABH-UHFFFAOYSA-N 0.000 description 1
- YBNPCJSZMYHDDR-UHFFFAOYSA-N 3-bromo-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(Br)=C1 YBNPCJSZMYHDDR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000785650 Homo sapiens Zinc finger protein 268 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010093175 Member 2 Group A Nuclear Receptor Subfamily 4 Proteins 0.000 description 1
- 102000002559 Member 2 Group A Nuclear Receptor Subfamily 4 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 101001109694 Rattus norvegicus Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102100026516 Zinc finger protein 268 Human genes 0.000 description 1
- GMQUEDBQYNHEEM-UHFFFAOYSA-N [B].[B].CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O Chemical compound [B].[B].CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O GMQUEDBQYNHEEM-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003683 electrophilic halogenation reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RWBYCMPOFNRISR-UHFFFAOYSA-N ethyl 4-chlorobenzoate Chemical compound CCOC(=O)C1=CC=C(Cl)C=C1 RWBYCMPOFNRISR-UHFFFAOYSA-N 0.000 description 1
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 229910001653 ettringite Inorganic materials 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSSJZLPUHJDYKF-UHFFFAOYSA-N methyl 4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1 QSSJZLPUHJDYKF-UHFFFAOYSA-N 0.000 description 1
- VNXBKJFUJUWOCW-UHFFFAOYSA-N methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- YVROHFXCFIJVCF-UHFFFAOYSA-N n-[2-(4-bromopyridin-2-yl)-1-(4-chlorophenyl)ethylidene]hydroxylamine Chemical compound C=1C=C(Cl)C=CC=1C(=NO)CC1=CC(Br)=CC=N1 YVROHFXCFIJVCF-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- YKVCWFPOJAXHGE-UHFFFAOYSA-N n-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound CNC(=O)C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 YKVCWFPOJAXHGE-UHFFFAOYSA-N 0.000 description 1
- NAQQTJZRCYNBRX-UHFFFAOYSA-N n-pentan-3-ylidenehydroxylamine Chemical compound CCC(CC)=NO NAQQTJZRCYNBRX-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
本發明係關於一種二苯基吡唑并吡啶衍生物,其製備及其在治療及預防涉及Nurr-1核受體(亦稱為NR4A2、NOT、TINUR、RNR-1及HZF3)之疾病中之治療用途。
本發明之一目的係有關式(I)化合物:
其中:R表示氫或鹵素原子或基團(C1-C6)烷基;X表示選自氫或鹵素原子及基團(C1-C6)烷基、鹵(C1-C6)烷基、(C1-C6)烷氧基、鹵(C1-C6)烷氧基、氰基、羥基或羥基(C1-C6)烷基之一或多個取代基;Y表示氫或鹵素原子或基團(C1-C6)烷基;R1表示基團NR2R3或OR4;R2及R3彼此獨立地表示氫原子或基團(C1-C6)烷基、羥基(C1-C6)烷基或側氧基(C1-C6)烷基,或者R2及R3與帶有其之氮原子形成視需要經基團(C1-C6)烷基、羥基或側氧基取代之雜環,R4表示基團(C1-C6)烷基、羥基(C1-C6)烷基或側氧基(C1-C6)烷基;其係呈鹼形式或酸加成鹽形式。
式(I)化合物可包括一或多個不對稱碳原子。因此其可存在有對映異構體或非對映異構體之形式。此等對映異構體及非對映異構體及其混合物(包括外消旋混合物)形成本發明之一部份。
式(I)化合物可以鹼形式或酸加成鹽形式存在。該加成鹽形成本發明之一部份。
此等鹽係利用醫藥上可接受酸製備,但用於(例如)純化或單離式(I)化合物之其他酸之鹽亦形成本發明之一部份。
式(I)化合物亦可以水合物或溶劑化物之形式,即以與一或多個水分子或與溶劑之結合物或組合物之形式存在。該水合物及溶劑化物亦形成本發明之一部份。
在本發明之上下文中,使用以下定義:
- 基團(Cx
-Ct
):包括x至t個碳原子之基團;
- 鹵素原子:氟、氯、溴或碘;
- 烷基:視需要經直鏈、分支鏈或環狀飽和烷基取代之直鏈、分支鏈或環狀飽和脂族基團。可提及之實例包括甲基、乙基、丙基、異丙基、丁基、異丁基、第三丁基、環丙基、環丁基、環戊基、環己基、甲基環丙基、環丙基甲基等基團;
- 烷氧基:基-O-烷基,其中該烷基基團係如先前所定義;
- 鹵烷基:經一或多個相同或不同的鹵素原子取代之烷基。可提及之實例包括基團CF3
、CH2
CF3
、CHF2
及CCl3
;
- 羥烷基:經羥基取代之烷基;可提及之實例包括CH2
OH、CH2
CH2
OH等;
- 側氧基烷基:經側氧基基團(C=O)取代之烷基;可提及之實例包括CH3
CO、CH3
COCH2
等;
- 鹵烷氧基:基-O-烷基,其中該烷基係如先前所定義及經一或多個相同或不同的鹵素原子取代。可提及之實例包括基團OCF3
、OCHF2
及OCCl3
;
- 芳基:包含6至10個碳原子之單環或雙環芳族基團。可提及之芳族基團之實例包括苯基及萘基;
- 雜環基團:包括5至9個碳原子、至少一個氮原子及視需要包括1至3個其他的雜原子(諸如氧、氮或硫)之飽和、含氮、視需要經橋接之環狀基團。可尤其提及哌啶基、哌嗪基、吡咯啶基、嗎啉基等基團。
在本發明目的之式(I)化合物中,第一類化合物係藉由以下化合物形成,其中:R表示氫或氯原子,X表示選自鹵素原子及基團(C1-C6)烷基、鹵(C1-C6)烷基、(C1-C6)烷氧基、鹵(C1-C6)烷氧基或氰基之一或多個取代基,Y表示氫原子、鹵素原子或基團(C1-C6)烷基;R1表示基團OR4,R4表示甲基;其係鹼形式或酸加成鹽形式。
在本發明目的之式(I)化合物中,第二類化合物係藉由以下化合物形成,其中:R表示氫或氯原子,X表示選自氯或氟原子及甲基、三氟甲基、甲氧基、三氟甲氧基或氰基之一或多個取代基,Y表示氫、氯或氟原子或甲基,R1表示基團OR4,R4表示甲基;其係呈鹼形式或酸加成鹽形式。
在本發明目的之式(I)化合物中,第三類化合物係藉由以下化合物形成,其中:R表示氫或氯原子,X表示選自鹵素原子及基團(C1-C6)烷基、鹵(C1-C6)烷基、(C1-C6)烷氧基、鹵(C1-C6)烷氧基或氰基之一或多個取代基,Y表示氫原子、鹵素原子或基團(C1-C6)烷基;R1表示基團NR2R3,R2及R3彼此獨立地表示氫原子或甲基、乙基、異丙基或環丙基基團,或者R2及R3與帶有其之氮原子形成視需要經羥基取代之嗎啉基或吡咯啶基;其係呈鹼形式或酸加成鹽形式。
在本發明目的之式(I)化合物中,第四類化合物係藉由以下化合物形成,其中:R表示氫或氯原子,X表示選自氯或氟原子及甲基、三氟甲基、甲氧基、三氟甲氧基或氰基之一或多個取代基,Y表示氫或氯原子或甲基,R1表示基團NR2R3,R2及R3彼此獨立地表示氫原子或甲基、乙基、異丙基或環丙基基團,或者R2及R3與帶有其之氮原子形成視需要經羥基取代之嗎啉基或吡咯啶基;其係呈鹼形式或酸加成鹽形式。
如上所定義之第一至第四類組合物亦形成本發明之一部份。
在本發明目的之式(I)化合物中,可尤其提及以下化合物:
●3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯
●3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺
●3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]-N,N-二甲基苯甲醯胺
●3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-異丙基苯甲醯胺
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N,N-二甲基苯甲醯胺
●{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}嗎啉-4-基-甲酮
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-2,N-二甲基苯甲醯胺
●2-氯-5-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●4-氯-3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-4,N-二甲基苯甲醯胺
●2-氟-4-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●N-環丙基-3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺
●{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}吡咯啶-1-基甲酮
●3-[2-(2,6-二氟苯基)吡唑并[1,5-α]吡啶-5-基-甲基苯甲醯胺
●3-[2-(2-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●N-甲基-3-[2-(4-三氟甲基苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺
●4-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●2-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}-(3-羥基吡咯啶-1-基)甲酮
●3-[2-(2,4-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●N-甲基-3-[2-(4-三氟甲氧基苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺
●3-[2-(3,4-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(3,5-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(3-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●N-甲基-3-(2-對甲苯基吡唑并[1,5-α]吡啶-5-基)苯甲醯胺
●3-[2-(4-甲氧基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(3,4-二甲基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(4-氰基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●3-[2-(2,3-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺
●N-甲基-3-(2-鄰甲苯基吡唑并[1,5-α]吡啶-5-基)苯甲醯胺
●3-[3-氯-2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺。
根據本發明,通式(I)化合物可根據反應圖1中所述之方法製備。
根據反應圖1,通式(Ia)化合物(其中R1表示OR4,R4表示烷基基團ALK,R表示氫原子,及X及Y係如先前所定義)可經由經金屬(諸如鈀)催化之通式(II)化合物(其中R表示氫原子,X係如先前所定義及Hal表示鹵素原子)與通式(III)化合物(其中Y及ALK係如先前所定義,及Z表示硼衍生物)之間的偶合反應而製備。
根據反應圖1,通式(Ib)化合物(其中R1表示OR4,R表示氫原子及X及Y係如先前所定義及R4表示氫原子)可經由通式(Ia)化合物與鹼(諸如含於含水醇介質中之氫氧化鈉)之水解反應製備。
根據反應圖1路徑A
,通式(Ic)化合物(其中R1表示NR2R3,R表示氫原子及X、Y、R2及R3係如先前所定義)可經由經金屬(諸如鈀)催化之通式(II)化合物(其中R表示氫原子,X係如先前所定義及Hal表示鹵素原子)與通式(IV)衍生物(其中Y、R2及R3係如先前所定義及Z表示硼衍生物)之間的偶合反應製備。
根據反應圖1路徑B
,通式(Ic)化合物(其中R1表示NR2R3,R表示氫原子及X、Y、R2及R3係如先前所定義)可在以溶液形式之三甲基鋁的存在下經由通式(Ia)化合物(其中R1表示OR4,R4表示烷基基團ALK,R表示氫原子及X及Y係如先前所定義)與通式(V)胺(其中R2及R3係如先前所定義)之間的反應或另外根據D. Glynn,D. Bernier及S. Woodward於Tetrahedron Letters,2008,49,5687-5688中所述之方法與三級胺(諸如DABCO)錯合而製備。
根據反應圖1路徑C
,通式(Ic)化合物(其中R1表示NR2R3,R表示氫原子及X、Y、R2及R3係如先前所定義)可在酸活化劑(氯甲酸異丁酯)的存在下經由通式(Ib)化合物(其中R1表示OR4,R表示氫原子,X及Y係如先前所定義及R4表示氫原子)與通式(V)胺(其中R2及R3係如先前所定義)之間的反應而製備。
根據反應圖1路徑D
,通式(Ic)化合物(其中R1表示NR2R3,R表示氫原子及X、Y、R2及R3係如先前所定義)可經由經金屬(諸如鈀)催化之通式(VI)化合物(其中R表示氫原子,X係如先前所定義及Z表示硼衍生物)與通式(VII)衍生物(其中Y、R2及R3係如先前所定義及Hal表示鹵素原子)之間的偶合反應而製備。
通式(Ic)化合物(其中R2及R3各表示氫原子)亦可根據反應圖2中所述之方法而準備。
在反應圖2中,通式(Ic)化合物(其中R1表示NH2,R表示氫原子及X及Y係如先前所定義)可(例如)在鹼的存在下,使用過氧化氫經由使通式(IX)腈水解而獲得。通式(IX)化合物可經由經金屬(諸如鈀)催化之通式(II)化合物(其中R表示氫原子,X係如先前所定義及Hal表示鹵素原子)與通式(VIII)衍生物(其中Y係如先前所定義,CN表示氰基及Z表示硼衍生物)之間的偶合反應而獲得。
根據本發明,通式(I)化合物可根據反應圖3中所述之方法而製備。
根據反應圖3,通式(Id)化合物(其中X、Y及R1係如先前所定義及R表示鹵素原子Hal)可使用諸如N-氯代琥珀醯亞胺之試劑經由化合物(Ia)或(Ic)之親電子鹵化作用(例如經由氯化作用)而製備。
根據本發明,通式(II)及(VI)化合物可根據反應圖4中所述之方法而製備。
在反應圖4路徑A
中,通式(II)化合物(其中X係如先前所定義,R表示氫原子及Hal表示鹵素原子)可(例如)根據Y. Tamura,J.-H. Kim,Y. Miki,H. Hayashi,M. Ikeda於J. Het. Chem.,1975
,12,481中所述之方法經由O-(均三甲苯基磺醯基)羥基胺(MSH)對通式(XIII)化合物(其中X及Hal係如先前所定義)之作用而製備。
在反應圖4路徑B
中,通式(II)化合物(其中X係如先前所定義,R表示氫原子及Hal表示鹵素原子)亦可(例如)根據K.S. Gudmundsson於Bioorg. Med. Chem.,2005
,13,5346中所述之方法,在鹼(諸如三乙胺)的存在下經由酸酐(諸如三氟酸酐)將通式(XIII)化合物轉化成通式(XIV)化合物(其中X及Hal係如先前所定義),繼而在觸媒(諸如氯化亞鐵)的存在下環化成通式(II)化合物而製備。
化合物(XIII)可經由羥基胺之作用自化合物(XII)獲得。化合物(XII)可(例如)根據K.S.Gudmundsson於Bioorg.Med.Chem.,2005
,13,5346中所述之方法,在強鹼的存在下自通式(X)甲基吡啶及自通式(XI)酯(其中X係如先前所定義及ALK表示烷基)獲得。
最終,化合物(VI)(其中Z表示硼衍生物)可(例如)根據E.F.DiMauro及R.Vitullo於J.Org.Chem.,2006
,71(10),3959中所述之方法,根據反應圖4經由經金屬(諸如鈀)催化之(例如)雙(頻那醇酯基)二硼與化合物(II)之偶合反應而製備。
在反應圖1、2、3及4中,該等起始化合物及試劑,當未闡述其製備方法時,則係購得或闡述於文獻中,或另外根據文中所述或為熟悉此項技術者所知曉之方法而製備。
根據其另一態樣,本發明之一目的亦係式(VI-1)化合物。此化合物可使用作為合成通式(I)化合物之中間物。
以下實例闡述根據本發明之某些化合物之製法。此等實例並不限制本發明,且僅作為闡述本發明之作用。該等實例之化合物之編號係指彼等在下文表中所給出者,其闡述數種根據本發明化合物之化學結構及物理特性。
在氮氣流下,將5 g(29.07 mmol)4-溴-2-甲基吡啶及11.27 g(61.04 mmol)4-氯苯甲酸乙酯置於圓底燒瓶中並溶於50 mL無水四氫呋喃中。將該溶液冷卻至5℃及逐滴添加70 mL(70 mmol)六甲基二矽氮烷鋰溶液(1 M含於四氫呋喃中)。在添加之後,將該混合物在室溫下攪拌2小時、冷卻至5℃,及隨後逐漸添加100 mL水。隨後將介質用250 mL乙酸乙酯及100 mL水稀釋。分離出有機相及將水相用100 mL乙酸乙酯萃取兩次。隨後組合有機相、用硫酸鈉乾燥及過濾。之後將15 g氧化矽添加至濾液中,隨後於減壓下濃縮。將所獲得之粉末用作於矽膠上層析之固體沈積物,以環己烷與乙酸乙酯之混合物(9/1)溶離。獲得8.4 g(93%)呈黃色粉末狀之化合物。
LC-MS: M+H=310
1
H NMR(DMSO)δ(ppm): 4.6(s,2H);6.4(s,1H);7.4(s,1H);自7.5至7.6(m,6H);7.7(s,1H);7.9(d,2H);8.1(d,2H);8.3(d,1H);8.4(d,1H);15.0(s,1H)(酮/烯醇混合物:40/60)。
將8.4 g(27.05 mmol)2-(4-溴吡啶-2-基)-1-(4-氯苯基)乙酮置於圓底燒瓶中之150 mL乙醇中。添加22 mL(272.56 mmol)吡啶及7.5 g(107.93 mmol)羥基胺單鹽酸鹽。隨後將混合物在室溫下攪拌5小時,及繼而將反應介質在減壓下濃縮直至獲得漿糊狀黃色固體為止,且將該固體溶於400 mL乙酸乙酯及400 mL水中。分離出有機相並將水相用200 mL乙酸乙酯萃取三次。隨後組合有機相、用硫酸鈉乾燥及過濾。將濾液在減壓下濃縮:獲得8.1 g(91.9%)呈藍色粉末形式之化合物。
LC-MS: M+H=325
1
H NMR(DMSO)δ(ppm): 4.3(s,2H);7.45(m,2H);7.50(d,1H);7.55(s,1H);7.75(m,2H);8.35(d,1H);11.65(s,1H)。
將12.9 g(45.21 mmol)O-(2-均三甲苯基磺醯基)乙醯羥肟酸乙酯置於圓底燒瓶中之30 mL 1,4-二噁烷中。將溶液冷卻至0℃及添加13.5 mL(156.60 mmol)過氯酸(70%水溶液)。隨後添加10 mL 1,4-二噁烷及將介質在0℃下劇烈攪拌2小時30分鐘。隨後將介質傾至350 mL冰冷水中。將介質於約0℃下放置10分鐘,及隨後藉由於燒結漏斗上過濾而回收生成之白色固體(不完全乾燥,因產物在呈乾燥形式時可能爆炸)。將所獲得之漿糊狀白色固體用350 mL冰冷水沖洗及隨後將其溶於冷卻至約5℃之250 mL 1,2-二氯乙烷及150 mL食鹽水中。回收有機相及經由疏水性濾筒過濾。回收濾液及將其逐滴添加至含於150 mL 1,2-二氯乙烷中之8.1 g(24.88 mmol)2-(4-溴吡啶-2-基)-1-(4-氯苯基)乙酮肟(步驟1.2中所獲得之化合物)之冷卻至約0℃之溶液中。
在添加之後,使混合物恢復至室溫及攪拌3小時。隨後連續地添加250 mL二氯甲烷、200 mL水及100 mL NaOH水溶液(1 N)至介質中。攪拌所得混合物及隨後藉由沉澱而分離相。分離有機相及將水相用200 mL二氯甲烷萃取兩次。隨後組合有機相、於疏水性濾筒(Radleys70 mL液/液萃取管柱)上過濾及隨後與15 g氧化矽混合。隨後將濾液在減壓下濃縮。獲得棕色粉末,其以固體沈積物使用於矽膠上層析,以環己烷與二氯甲烷之混合物(1/1)溶離。獲得5.8 g(75%)呈淺黃色毛絨狀固體狀之化合物。
LC-MS: M+H=307。
1
H NMR(DMSO)δ(ppm): 7.0(d,1H);7.1(s,1H);7.6(d,2H);8.0(s,1H);8.1(d,2H);8.7(d,1H)。
將步驟1.3中獲得之0.235 g(0.76 mmol)5-溴-2-(4-氯苯基)吡唑并[1,5-α]吡啶、0.165 g(0.92 mmol)3-甲氧基羰基苯基酸、0.750 g(2.30 mmol)碳酸銫及0.065 g(0.08 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)在5 mL THF-水混合物(9/1)的存在下置於存圓底燒瓶中。隨後將介質在70℃下保持1小時30分鐘,及隨後將其冷卻至室溫及用30 mL二氯甲烷及30 mL水稀釋。將兩相介質於疏水性濾筒(Radleys70 mL液/液萃取管柱)上過濾及隨後將濾液在減壓下濃縮:將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(8/2)溶離。獲得0.200 g(72%)呈淺褐色粉末狀之預期之化合物。
熔點(℃):180-182
LC-MS: M+H=363
1
H NMR(DMSO)δ(ppm): 3.95(s,3H);7.20(s,1H);7.35(d,1H);7.60(d,2H);7.70(t,1H);自8.00至8.20(m,5H);8.35(s,1H);8.85(d,1H)。
將根據步驟1.3之規程所獲得之0.850 g(2.76 mmol)5-溴-2-(4-氯苯基)吡唑并[1,5-α]吡啶在20 mL THF-水混合物(9/1)的存在下置於具有0.490 g(3.33 mmol)3-氰基苯基酸、2.70 g(8.29 mmol)碳酸銫及0.225 g(0.26 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)之圓底燒瓶中。隨後將介質在75℃下保持3小時,繼而另外添加0.245 g(1.66 mmol)3-氰基苯基酸、1.35 g(4.14 mmol)碳酸銫及0.115 g(0.14 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)及將介質在75℃下攪拌1小時30分鐘。隨後將介質用100 mL乙酸乙酯及100 mL水稀釋。之後回收有機相並將水相用100 mL乙酸乙酯萃取兩次。隨後組合有機相、用硫酸鈉乾燥及過濾。隨後將濾液在減壓下濃縮及將所獲得之殘餘物溶於四氫呋喃中及使其在減壓下濃縮,繼而添加10 g氧化矽。將殘餘物於矽膠上層析,以環己烷與乙酸乙酯之混合物(8/2)溶離。獲得0.185 g(20.2%)呈白色粉末狀之預期化合物。
LC-MS: M+H=330
1
H NMR(DMSO)δ(ppm): 7.19(s,1H);7.37(dd,1H);7.56(m,2H);7.74(t,1H);7.90(m,1H);8.06(m,2H);自8.15至8.24(m,2H);8.35(m,1H);8.82(d,1H)。
將於步驟2.1中所獲得之0.150 g(0.45 mmol)[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲腈置於具有5 mL無水二甲亞碸之圓底燒瓶中。將介質冷卻至約10℃及添加0.100 mL(1.17 mmol)水性過氧化氫溶液(35%水溶液)及0.035 g(0.25 mmol)碳酸鉀。將介質逐漸溫和加熱至室溫並攪拌1小時。繼而將介質冷卻至約5℃及添加0.500 mL(5.85 mmol)過氧化氫及0.250 g(1.78 mmol)碳酸鉀。隨後將介質在室溫下攪拌1小時30分鐘,繼而用50 mL水稀釋。將介質經由燒結漏斗過濾,及回收粉末,將其於矽膠上進行層析(藉由固體沈積),並以二氯甲烷與甲醇之混合物(9/1)溶離。獲得0.090 g(56.8%)呈白色粉末狀之預期化合物。
熔點(℃):283-285
LC-MS: M+H=348
1
H NMR(DMSO)δ(ppm): 7.17(s,1H);7.36(dd,1H);7.47(s,1H);7.56(m,2H);7.61(t,1H);7.94(m,1H);8.00(m,1H);8.07(m,2H);8.11(m,1H);8.15(s,1H);8.32(m,1H);8.82(d,1H)。
在氮氣流下,將0.900 mL(1.80 mmol)二甲基胺溶液(2 M含於四氫呋喃中)及8 mL甲苯置於圓底燒瓶中。隨後將介質冷卻至約0℃及繼而逐滴添加0.900 mL(1.80 mmol)三甲基鋁溶液(2 M含於甲苯中)。在添加之後,將介質在約0℃下攪拌25分鐘,繼而添加於步驟2.1中所獲得之0.200 g(0.55 mmol)3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯。隨後將介質在90℃下保持3小時,繼而冷卻至約0℃。繼而藉由逐滴添加10 mL鹽酸溶液(1 N)而將介質水解。添加後,將介質回溫至室溫及隨後用60 mL二氯甲烷及60 mL水稀釋。用氫氧化鈉溶液(1 N)將水相之pH調節至約11及將所獲得之兩相介質於經Celite填充之燒結漏斗上過濾。回收濾液並使其通過疏水性濾筒(Radleys70 mL液/液萃取管柱)。在添加1.2 g氧化矽石之後,回收濾液並於減壓下濃縮。將所獲得之殘餘物進行矽膠層析,以環己烷與乙酸乙酯之混合物(3/7)溶離。
獲得0.121 g(58.4%)呈白色粉末狀之預期化合物。
熔點(℃):175-177
LC-MS: M+H=376
1
H NMR(DMSO)δ(ppm): 3.02(d,6H);7.15(s,1H);7.35(dd,1H);7.46(m,1H);自7.50至7.67(m,3H);7.85(m,1H);7.91(m,1H);自8.00至8.15(m,3H);8.80(d,1H)。
根據實例3中所述之程序進行製程,用含於8 mL甲苯中之步驟3.1中所獲得之0.200 g(0.55 mmol)3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯、0.900 mL(1.80 mmol)甲基胺溶液(2 M含於四氫呋喃中)及0.900 mL(1.80 mmol)三甲基鋁溶液(2 M含於甲苯中)起始。在矽膠上層析,用環己烷與乙酸乙酯之混合物(1/1)溶離後,獲得0.151 g(75.6%)呈白色粉末狀之預期化合物。
熔點(℃):234-236
LC-MS: M+H=362
1
H NMR(DMSO)δ(ppm): 2.85(d,3H);7.18(s,1H);7.35(m,1H);自7.51至7.68(m,3H);7.90(m,1H);8.00(m,1H);自8.02至8.12(m,3H);8.28(m,1H);8.62(m,1H);8.82(d,1H)。
在氮氣流下,將5.0 g(29.07 mmol)4-溴-2-甲基吡啶及10.2 g(60.95 mmol)4-氟苯甲酸乙酯置於圓底燒瓶中並將其溶於50 mL無水四氫呋喃中。將混合物冷卻至0℃並逐滴添加70 mL(70 mmol)六甲基二矽氮烷鋰溶液(1 M含於四氫呋喃中)。添加後,將混合物在室溫下攪拌2小時,冷卻至5℃,及隨後逐漸添加100 mL水。之後將介質用250 mL乙酸乙酯及100 mL水稀釋。分離有機相及將水相用100 mL乙酸乙酯萃取兩次。隨後組合有機相、用硫酸鈉乾燥及過濾。隨後將15 g氧化矽添加至濾液中,及攪拌所得混合物及繼而在減壓下濃縮。將所獲得之粉末使固體沉積物使用於矽膠層析,以環己烷與乙酸乙酯之混合物(9/1)溶離。獲得7.5 g(88%)呈黃色粉末狀之化合物。
LC-MS: M+H=294(酮/烯醇比率:43/57)
1
H NMR(DMSO)δ(ppm): 4.56(s,2H);6.34(s,1H);自7.23至7.40(m,5H);7.53(d,1H);7.56(m,1H);7.70(d,1H);自7.81至7.92(m,2H);自8.04至8.16(m,2H);8.29(d,1H);8.37(d,1H);15.0(s,1H)。
將7.5 g(24.26 mmol)2-(4-溴吡啶-2-基)-1-(4-氟苯基)乙酮置於包含100 mL無水乙醇之圓底燒瓶中。添加20 mL(247.78 mmol)吡啶及7.08 g(101.88 mmol)羥基胺單鹽酸鹽,及隨後將介質在室溫下攪拌3小時。隨後使乙醇在減壓下蒸發及將所獲得之殘餘物溶於250 mL水及250 mL乙酸乙酯中。分離有機相及隨後將水相用150 mL乙酸乙酯萃取5次。繼而組合有機相、用硫酸鈉乾燥及在減壓下濃縮。獲得7.82 g化合物。
LC-MS: M+H=309
1
H NMR(DMSO-d6
,δ以ppm計): 4.26(s,2H);7.19(t,2H);7.50(m,2H);7.75(m,2H);8.33(d,1H);11.50(s,1H)(產生肟(E))。
將7.82 g(25.50 mmol)2-(4-溴吡啶-2-基)-1-(4-氟苯基)乙酮肟置於圓底燒瓶中並溶於400 mL 1,2-二氯乙烷中。將O-(均三甲苯基磺醯基)羥基胺溶液(0.27 M含於1,2-二氯乙烷中-根據步驟1.3中所述規程而獲得之化合物)逐滴添加至冷卻至約0℃之介質中。添加後,將介質在室溫下攪拌1小時30分鐘。隨後將介質用200 mL水及200 mL氫氧化鈉溶液(1 N)稀釋。攪拌兩相介質並隨後將該等相藉由沉澱分離。分離有機相及隨後將水相用200 mL二氯甲烷萃取4次。隨後組合有機相、用硫酸鈉乾燥及過濾。繼而將15 g氧化矽添加至濾液中,及之後將所得混合物在加壓下濃縮。將所獲得之粉末用作於矽膠上層析之固體沉積物,以環己烷與二氯甲烷之混合物(1/1)溶離。獲得5.06 g(68%)呈毛絨狀白色粉末狀之化合物。
LC-MS: M+H=291
1
H NMR(DMSO-d6
,δ以ppm計):自7.00至7.10(m,2H);7.45(m,2H);8.05(m,3H);8.70(d,1H)。
在氮氣流下,將於步驟5.3中所獲得之0.400 g(1.37 mmol)5-溴-2-(4-氟苯基)吡唑并[1,5-α]吡啶、0.300 g(1.67 mmol)3-甲氧基羰基苯基酸及1.330 g(4.08 mmol)碳酸銫置於5 mL四氫呋喃與水之9/1混合物中。添加0.11 g(0.13 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)及隨後將介質在70℃下加熱4小時。隨後將介質冷卻至室溫並用40 mL二氯甲烷及40 mL水稀釋。隨後將介質於疏水性濾筒(Radleys70 mL液/液萃取管柱)上過濾並在添加2 g氧化矽之後回收有機相及在減壓下濃縮。將殘餘物於矽膠上層析,以環己烷與乙酸乙酯之混合物(9/1)溶離而純化。獲得0.340 g(71%)呈白色粉末狀之所預期之產物。
根據實例3中所述之程序進行製程,用含於8 mL甲苯中之步驟7.4中所獲得之0.200 g(0.58 mmol)3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯、1.00 mL(2.00 mmol)甲基胺溶液(2 M含於四氫呋喃中)及1.00 mL(2.00 mmol)三甲基鋁溶液(2 M含於甲苯中)起始。在矽膠上層析,以環己烷與乙酸乙酯之混合物(1/1)溶離之後,回收0.235 g(67.7%)呈白色粉末狀之預期化合物。
熔點(℃):214-216
LC-MS: M+H=346
1
H NMR(DMSO)δ(ppm): 2.85(d,3H);7.15(s,1H);自7.26至7.46(m,3H);7.62(m,1H);7.90(m,1H);8.00(m,1H);自8.05至8.21(m,3H);8.29(m,1H);8.60(m,1H);8.82(d,1H)。
使步驟7.3中所獲得之1.00 g(3.43 mmol)5-溴-2-(4-氟苯基)吡唑并[1,5-α]吡啶與含於14 mL二噁烷中之1.05 g(4.13 mmol)雙(頻哪醇酯基)二硼、1.00 g(10.19 mmol)乙酸鉀及0.280 g(0.34 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)接觸。
將所獲得之介質在140℃下經微波照射20分鐘,及隨後用100 mL二氯甲烷及100 mL水稀釋。隨後將兩相介質經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。在添加4 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上層析,以環己烷與乙酸乙酯之混合物(9/1)溶離。
獲得0.992 g(85.4%)呈粉色粉末狀之預期化合物。
LC-MS: M+H=338(在管柱上降解成酸M+H=257)
1
H NMR(DMSO)δ(ppm): 1.35(s,12H);7.00(m,1H);7.19(s,1H);7.34(t,2H);8.05(m,3H);8.69(d,1H)。
將0.500 g(2.33 mmol)3-溴-2-甲基苯甲酸在1.51 mL(10.83 mmol)三乙胺、0.408 g(3.02 mmol)N-羥基苯并三唑單水合物、0.579 g(3.02 mmol)1-(3-二甲胺基丙基)-3-乙基碳化二醯亞胺單鹽酸鹽及5 mL二氯甲烷存在下置於圓底燒瓶中。將介質在室溫下攪拌1小時,繼而添加1.51 mL(3.02 mmol)甲基胺溶液(2 M含於四氫呋喃中)。將介質在室溫下攪拌過夜,繼而另外添加0.5 mL(1 mmol)甲基胺溶液,及將該混合物攪拌過夜。隨後將介質在減壓下濃縮,及添加5 mL二氯甲烷及0.390 mL(2.99 mmol)氯甲酸異丁酯。將介質再次攪拌過夜,繼而用7 mL二氯甲烷及7 mL水稀釋。隨後將介質於疏水性濾筒(Radleys70 mL液/液萃取管柱)上過濾。回收有機相並在減壓下濃縮。
獲得0.298 g(56.2%)呈白色粉末狀之預期化合物。
LC-MS: M+H=228
1
H NMR(DMSO)δ(ppm): 2.31(s,3H);2.80(d,3H);自7.05至7.35(m,2H);7.68(m,1H);8.32(bs,1H)。
使步驟7.1中所獲得之0.150 g(0.44 mmol)2-(4-氟苯基)-5-(4,4,5,5-四甲基-[1,3,2]二氧硼雜環戊-2-基)吡唑并[1,5-α]吡啶及步驟10.2中所獲得之0.144 g(0.63 mmol)3-溴-2-N-二甲基苯甲醯胺與含於5 mL四氫呋喃與水之9/1混合物中之0.434 g(1.33 mmol)碳酸銫及0.036 g(0.044 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)接觸。將介質在60℃下攪拌過夜。隨後將介質用50 mL二氯甲烷及50 mL水稀釋。隨後將兩相介質於疏水性濾筒(Radleys70 mL液/液萃取管柱)上過濾。在添加1.5 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上層析,以環己烷與乙酸乙酯之混合物(1/1)溶離。
獲得0.103 g(65%)呈白色粉末狀之預期化合物。
熔點(℃):240-242
LC-MS: M+H=360
1
H NMR(DMSO)δ(ppm): 2.37(s,3H);2.80(d,3H);6.86(d,1H);7.10(s,1H);自7.33至7.44(m,5H);7.63(s,1H);8.10(m,2H);8.28(s,1H);8.76(d,1H)。
將0.0382 g(0.67 mmol)環丙基胺用10 mL無水四氫呋喃稀釋。隨後逐漸添加0.0859 g(0.33 mmol)DABAL(三甲基鋁與1,4-二氮雜雙環[2.2.2]辛烷之雙重加成物),及繼而將介質攪拌1小時。隨後添加根據規程5.4所獲得之0.145 g(0.42 mmol)3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯,及繼而將該反應介質於微波爐中在130℃下照射30分鐘兩次。隨後使用5 mL水及5 mL鹽酸水溶液(1 N)將介質在約5℃下水解。水解後,將介質用50 mL水及50 mL二氯甲烷稀釋,及隨後經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。在添加1.5 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(6/4)溶離。
獲得0.112 g(72.3%)呈白色粉末狀之預期化合物。
熔點(℃):179-181
LC-MS: M+H=372
1
H NMR(DMSO)δ(ppm):自0.60至0.80(m,4H);3.92(m,1H);7.15(s,1H);自7.30至7.39(m,3H);7,61(t,1H);7.88(d,1H);7.98(d,1H);8.10(m,3H);8.22(s,1H);8.57(m,1H);8.81(d,1H)。
將根據實例8中製備之0.100 g(0.30 mmol)3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸在0.170 mL(1.20 mmol)三乙胺及20 mL二氯甲烷存在下置於圓底燒瓶中。隨後添加0.051 μL(0.39 mmol)氯甲酸異丁酯及將介質在室溫下攪拌2小時。將0.0341 g(0.39 mmol)3-羥基吡咯啶添加至介質中,將其在室溫下又攪拌2小時。隨後將介質用50 mL水及50 mL二氯甲烷稀釋。隨後將兩相介質經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。添加1 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(6/4)溶離。
獲得0.063 g(50%)呈淺黃色蠟狀之預期化合物。
熔點(℃):173-175
LC-MS: M+H=402
1
H NMR(DMSO)δ(ppm):自1.65至2.05(m,2H);自3.40至3.70(m,4H);4.32(d,1h);5.00(d,1H);7.11(s,1H);7.32(m,3H);7.60(m,2H);7.93(d,2H);8.08(m,3H);8.77(d,1H)。
在氮氣流下,將1 g(5.81 mmol)4-溴-2-甲基吡啶及1.75 g(11.60 mmol)4-甲基苯甲酸甲酯置於圓底燒瓶中並溶於30 mL無水四氫呋喃中。將溶液冷卻至5℃並逐滴添加14 mL(14 mmol)六甲基二矽氮烷鋰溶液(1 M含於四氫呋喃中)。添加後,將混合物在室溫下攪拌2小時30分鐘及隨後冷卻至5℃,繼而逐漸添加20 mL水。隨後將介質用200 mL乙酸乙酯及200 mL水稀釋。分離有機相,用硫酸鈉乾燥及過濾。隨後添加5 g氧化矽至濾液中,繼而將其在減壓下濃縮。將所獲得之粉末用作於矽膠上層析之固體沉積物,以環己烷與乙酸乙酯之混合物(95/5)溶離,獲得1.03 g(61%)呈黃色粉末狀之化合物。
LC-MS: M+H=290
將步驟13.1中所獲得之1.03 g 2-(4-溴吡啶-2-基)-1-對甲苯基乙酮置於具有0.99 g(14.2 mmol)羥基胺單鹽酸鹽、3 mL(37 mmol)吡啶及100 mL乙醇之圓底燒瓶中。將反應介質攪拌過夜及隨後在減壓下濃縮。隨後將所獲得之殘餘物溶於200 mL乙酸乙酯及200 mL水中。回收有機相,用硫酸鈉乾燥及隨後在減壓下濃縮。回收1.10 g化合物並將其溶於包含0.660 mL(4.74 mmol)三乙胺及30 mL二氯甲烷之圓底燒瓶中。隨後將反應介質冷卻至約5℃及逐滴添加0.200 mL(1.42 mmol)三氟乙酸酐。之後將介質在室溫下攪拌3小時,繼而經100 mL水水解。隨後將介質攪拌10分鐘,繼而經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。之後添加1.2 g氧化矽至濾液中,繼而在減壓下濃縮。將所獲得之粉末用作於矽膠上層析之固體沉積物,以環己烷與乙酸乙酯之混合物(95/5)溶離。回收0.746 g(77%)呈白色粉末狀之預期化合物。
1
H NMR(DMSO)δ(ppm): 2.42(d,3H);3.45(s,1H);自7.42至7.58(m,4H);7.78(m,2H);8.30(d,1H)。
將步驟13.2中所獲得之0.746 g 4-溴-2-(3-對甲苯基-2H-氮雜環丙烯-2-基)吡啶在6.6 mg(0.052 mmol)氯化亞鐵(II)的存在下溶於30 mL 1,2-二甲氧基乙烷中。隨後將介質回流6小時。之後另外添加10 mg(0.078 mmol)氯化亞鐵(II)並將混合物伴隨著攪拌再次回流3小時。隨後用50 mL乙酸乙酯及50 mL水稀釋介質。之後回收有機相,用硫酸鈉乾燥及過濾。隨後添加2 g氧化矽至濾液中,繼而在減壓下濃縮。將所獲得之粉末用作於矽膠上層析之固體沉積物,以環己烷與乙酸乙酯之混合物(85/15)溶離。回收0.534 g(71%)呈黃色粉末狀之預期化合物。
LC-MS: M+H=287
1
H NMR(DMSO)δ(ppm): 2.48(m,3H);7.00(m,2H);7.32(m,2H);7.88(m,2H);8.00(m,1H);8.68(d,1H)。
使2.50 g(11.68 mmol)3-溴-N-甲基苯甲醯胺、3.56 g(14.01 mmol)雙(頻那醇酯基)二硼、3.43 g(35.04 mmol)乙酸鉀及0.953 g(1.17 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)與20 mL二噁烷接觸,及隨後經微波在130℃下照射45分鐘。隨後將介質用150 mL乙酸乙酯及100 mL水稀釋。回收有機相及將水相用100 mL乙酸乙酯萃取兩次。隨後組合有機相,用硫酸鈉乾燥及繼而在添加10 g氧化矽之後於減壓下濃縮。將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(8/2)溶離。
獲得1.39 g呈粉色粉末狀之預期化合物(存在頻那醇(pinacol))。
1
H NMR(DMSO)δ(ppm): 1.30(s,12H);2.78(d,3H);7.48(t,1H);7.80(m,1H);7.95(m,1H);8.12(m,1H);8.50(m,1H)。
將步驟13.3中所獲得之0.150 g(0.52 mmol)5-溴-2-對甲苯基吡唑并[1,5-α]吡啶、步驟13.4中所獲得之0.136 g(0.52 mmol)N-甲基-3-(4,4,5,5-四甲基-[1,3,2]二氧硼雜環戊-2-基)苯甲醯胺、0.510 g(1.57 mmol)碳酸銫及0.043 g((0.05 mmol)[1,1'-雙(二苯基膦基)二茂鐵]二氯鈀(II)置於5 mL四氫呋喃與水之9/1混合物中。將介質在65℃下攪拌4小時。隨後將介質用50 mL二氯甲烷及50 mL水稀釋。隨後將兩相介質經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。在添加1.5 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(1/1)溶離。
獲得0.138 g(77.7%)呈淺褐色粉末狀之預期化合物。
熔點(℃):204-206
LC-MS: M+H=342
1
H NMR(DMSO)δ(ppm): 2.38(s,3H);2.85(d,3H);7.10(s,1H);7.31(m,3H);7.62(t,1H);7.90(m,3H);7.98(d,1H);8.08(s,1H);8.29(s,1H);8.61(d,1H);8.81(d,1H)。
將根據規程6所獲得之0.100 g(0.29 mmol)3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺在3 mL二氯甲烷存在下置於圓底燒瓶中。添加0.060 g(0.45 mmol)N-氯代琥珀醯亞胺,及介質隨後在室溫下攪拌過夜。之後將反應介質用50 mL二氯甲烷及50 mL水稀釋。繼而將兩相介質經由疏水性濾筒(Radleys70 mL液/液萃取管柱)過濾。在添加1.2 g氧化矽之後,回收有機相並在減壓下濃縮。將所獲得之殘餘物於矽膠上進行層析,以環己烷與乙酸乙酯之混合物(6/4)溶離。
獲得0.0592 g(53.8%)呈白色粉末狀之預期化合物。
熔點(℃):221-223
LC-MS: M+H=380
1
H NMR(DMSO)δ(ppm): 2.88(d,3H);7.42(m,2H);7.47(dd,1H);7.64(t,1H);7.93(m,1H);8.01(m,1H);8.05(m,1H);8.10(m,2H);8.31(m,1H);8.63(m,1H);8.88(d,1H)。
下表闡述通式(I)之化學結構(表1)及多數根據本發明之化合物實例之物理特徵(表2).
在此等表中:
- 「m.p.」欄表示以攝氏度(℃)計之產物熔點;
- Me及Et分別表示甲基及乙基;
- *表示結合原子。
使本發明之化合物經歷藥理學測試以用於測定其對NOT之調節作用。
評估根據本發明之化合物對於內生性地表現鼠科Nurrl受體及經偶合至螢光素酶報告子基因之NOT結合反應元素(NBRE)穩定地轉染之細胞株(N2A)上之活性。根據下文所述之程序進行測試。
該細胞株Neuro-2A係獲自標準商業來源(ATCC)。Neuro-2A純系係由R.J Klebe等人自白化小鼠A之自發性腫瘤獲得。隨後將此細胞株Neuro-2A穩定地經8NBRE-螢光素酶轉染。於包含經10%胎牛血清、4.5 g/L葡萄糖及0.4 mg/ml慶大黴素(geneticin)補充之含DMEM的75 cm2
培養燒瓶中培養N2A-8NBRE細胞直至匯合。在培養一週之後,用0.25%胰蛋白酶回收此等細胞30秒及隨後再懸浮於不含酚紅、包含4.5 g/L葡萄糖及10% Hyclone脫脂血清之DMEM中,並將其置於底部白色透明之96孔板中。在添加產物之前將該等細胞以60000個每孔(75 μL)之比率沈積24小時。施用25 μL產物並再培養24小時。在測量的當天,添加等體積(100 μL)的Steadylite至各孔,及隨後將該等孔靜置30分鐘以獲得完全的細胞溶解及最大信號產生。繼而在用膠黏膜密封之後,將該等板於微量盤發光計數器中測量。以10-2
M原液之形式製備該等產物,及隨後於100% DMSO中稀釋。將各濃度的產物在經細胞培養之前於培養基中預稀釋,藉此最終包含0.625% DMSO。
最佳化合物具有0.1 nM至10 μM之間的EC50
值。
例如,已顯示化合物2、4、10、14、16及26分別具有45、2、6.6、125、326及1.3 nM之EC50
值。
因此,可看出根據本發明之化合物對NOT具有調節作用。
因此,根據本發明之化合物可用於製備其用於治療或預防涉及NOT受體之疾病之治療應用的藥劑。
因此,根據其另一態樣,本發明之一目的係包括式(I)化合物或其與醫藥上可接受酸之加成鹽之藥劑。
此等藥劑發現其治療用途,尤其係治療及預防神經退化性疾病,例如帕金森氏症(Parkinson's disease)、阿茲海默氏症(Alzheimer's disease)、Tau-蛋白病(tauopathy)(例如進行性核上麻痹、額顳葉型失智症、皮質基底核退化症、皮克病(Pick's disease));腦創傷,例如缺血及頭顱創傷及癲癇;精神病,例如精神分裂症、抑鬱症、藥物依賴、及注意力不足過動障礙症;中樞神經系統之炎症性疾病,例如多發性硬化、腦炎、脊髓炎及腦脊髓炎及其他炎症性疾病,例如血管病理、動脈粥樣硬化、關節炎、關節病、風濕性關節炎;骨關節炎、克羅恩病(Crohn's disease)、潰瘍性結腸炎;過敏性炎症性疾病,諸如哮喘、自身免疫性疾病,例如1型糖尿病、狼瘡、硬皮病、吉蘭-巴雷綜合徵(Guillain-Barrsyndrome)、阿狄森氏病(Addison's disease)及其他免疫介導之疾病;骨質疏鬆症;癌症。
此等化合物亦可用作與接枝及/或幹細胞移植結合之治療。
根據其另一態樣,本發明係關於一種包括作為活性成份之根據本發明之化合物之醫藥組合物。此等醫藥組合物包含有效劑量的至少一種根據本發明之化合物,或該化合物之醫藥上可接受鹽,亦及至少一種醫藥上可接受賦形劑。
該等賦形劑係根據醫藥形式及所需投藥模式自熟悉此項技術者所知曉之常見賦形劑選出。
在用於口服、舌下、皮下、肌肉內、靜脈內、局部、表面、氣管內、鼻內、經皮或直腸投與之本發明之醫藥組合物中,以上式(I)活性成份或其鹽可作為與標準醫藥賦形劑之混合物,以單位投與形式投與至人類及動物,用於預防或治療以上病症或疾病。
適宜的單位投藥形式包括口服形式,諸如錠劑、軟或硬凝膠膠囊、粉末、顆粒及口服溶液或懸浮液;舌下、口腔、氣管內、眼內、鼻內或吸入投與形式;局部、經皮、皮下、肌肉內或靜脈內投與形式;直腸投與形式及植入。對於局部應用,根據本發明之化合物可以乳霜、凝膠、軟膏或洗液使用。
舉例而言,以錠劑形式之根據本發明之化合物之單位投藥形式可包括以下組分:
本發明化合物 50.0 mg
甘露醇 223.75 mg
交聯羧甲纖維素鈉 6.0 mg
玉米澱粉 15.0 mg
羥基丙基甲基纖維素 2.25 mg
硬脂酸鎂 3.0 mg
可存在更高或更低劑量仍為適宜之特別情況,該等劑量並未超出本發明之內容。根據通常實際操作,適用於各患者之劑量係藉由醫生根據投藥模式及該患者之體重及反應而決定。
根據其另一態樣,本發明亦係關於一種治療以上所指之病理學之方法,其包括對患者投與有效量的本發明化合物或其醫藥上可接受鹽。
Claims (17)
- 一種式(I)之化合物,
- 如請求項1之式(I)化合物,其特徵為:R表示氫或氯原子,X表示選自鹵素原子及基團(C1-C6)烷基、鹵(C1-C6)烷基、(C1-C6)烷氧基、鹵(C1-C6)烷氧基或氰基之一或多個取代基,Y表示氫原子、鹵素原子或基團(C1-C6)烷基;R1表示基團OR4,R4表示甲基;其係呈鹼或酸加成鹽形式。
- 如請求項1之式(I)化合物,其特徵為:R表示氫或氯原子,X表示選自氯或氟原子及甲基、三氟甲基、甲氧基、三氟甲氧基或氰基之一或多個取代基,Y表示氫、氯或氟原子或甲基,R1表示基團OR4,R4表示甲基;其係呈鹼或酸加成鹽形式。
- 如請求項1之式(I)化合物,其特徵為:R表示氫或氯原子,X表示選自鹵素原子及基團(C1-C6)烷基、鹵(C1-C6)烷基、(C1-C6)烷氧基、鹵(C1-C6)烷氧基或氰基之一或多個取代基,Y表示氫原子、鹵素原子或基團(C1-C6)烷基; R1表示基團NR2R3,R2及R3彼此獨立地表示氫原子或甲基、乙基、異丙基或環丙基基團,或者R2及R3與帶有其之氮原子形成未經取代或經羥基取代之嗎啉基或吡咯啶基;其係呈鹼或酸加成鹽形式。
- 如請求項1之式(I)化合物,其特徵為:R表示氫或氯原子,X表示選自氯或氟原子及甲基、三氟甲基、甲氧基、三氟甲氧基或氰基之一或多個取代基,Y表示氫或氯原子或甲基,R1表示基團NR2R3,R2及R3彼此獨立地表示氫原子或甲基、乙基、異丙基或環丙基基團,或者R2及R3與帶有其之氮原子形成未經取代或經羥基取代之嗎啉基或吡咯啶基;其係呈鹼或酸加成鹽形式。
- 一種化合物,其係:˙3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯˙3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺˙3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]-N,N-二甲基苯甲醯胺˙3-[2-(4-氯苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲酸甲酯˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲 醯胺˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-異丙基苯甲醯胺˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N,N-二甲基苯甲醯胺˙{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}嗎啉-4-基-甲酮˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-2,N-二甲基苯甲醯胺˙2-氯-5-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙4-氯-3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-4,N-二甲基苯甲醯胺˙2-氟-4-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙N-環丙基-3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺˙{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}吡咯啶-1-基甲酮˙3-[2-(2,6-二氟苯基)吡唑并[1,5-α]吡啶-5-基-甲基苯甲醯胺˙3-[2-(2-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲 醯胺˙N-甲基-3-[2-(4-三氟甲基苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺˙4-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙2-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙{3-[2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]苯基}-(3-羥基吡咯啶-1-基)甲酮˙3-[2-(2,4-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙N-甲基-3-[2-(4-三氟甲氧基苯基)吡唑并[1,5-α]吡啶-5-基]苯甲醯胺˙3-[2-(3,4-二氟苯基)吡唑并[1,5-α]吡啶-5-基]N-甲基苯甲醯胺˙3-[2-(3,5-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙3-[2-(3-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙N-甲基-3-(2-對甲苯基吡唑并[1,5-α]吡啶-5-基)苯甲醯胺˙3-[2-(4-甲氧基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙3-[2-(3,4-二甲基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲 基苯甲醯胺˙3-[2-(4-氰基苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙3-[2-(2,3-二氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺˙N-甲基-3-(2-鄰甲苯基吡唑并[1,5-α]吡啶-5-基)苯甲醯胺,及˙3-[3-氯-2-(4-氟苯基)吡唑并[1,5-α]吡啶-5-基]-N-甲基苯甲醯胺。
- 一種藥劑,其特徵為其包括如請求項1至6中任一項之式(I)化合物或該化合物與醫藥上可接受酸之加成鹽。
- 一種醫藥組合物,其特徵為其包括如請求項1至6中任一項之式(I)化合物,或該化合物之醫藥上可接受鹽,及至少一種醫藥上可接受之賦形劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防神經退化性疾病之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防腦創傷及癲癇之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防精神病之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防炎症性疾病之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防骨質疏鬆症及癌症之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防帕金森氏症(Parkinson's disease)、阿茲海默氏症(Alzheimer's disease)、Tau-蛋白病(tauopathy)及多發性硬化之藥劑。
- 一種如請求項1至6中任一項之式(I)化合物之用途,其係用於製備用於治療及預防精神分裂症、抑鬱症、藥物依賴及注意力不足過動障礙症之藥劑。
- 一種式(VI-1)之中間化合物,
- 一種如請求項16之化合物用於合成如請求項1之通式(I)產物之用途。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0958651A FR2953520B1 (fr) | 2009-12-04 | 2009-12-04 | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201129564A TW201129564A (en) | 2011-09-01 |
TWI481606B true TWI481606B (zh) | 2015-04-21 |
Family
ID=42111360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099142230A TWI481606B (zh) | 2009-12-04 | 2010-12-03 | 二苯基吡唑并吡啶衍生物、其製備及其治療用途 |
Country Status (24)
Country | Link |
---|---|
US (1) | US8680096B2 (zh) |
EP (1) | EP2507238B1 (zh) |
JP (1) | JP5738310B2 (zh) |
KR (1) | KR101696959B1 (zh) |
CN (1) | CN102762559B (zh) |
AR (1) | AR079250A1 (zh) |
AU (1) | AU2010326429B2 (zh) |
BR (1) | BR112012013511A2 (zh) |
CA (1) | CA2782704C (zh) |
CL (1) | CL2012001461A1 (zh) |
CO (1) | CO6551713A2 (zh) |
EA (1) | EA020652B1 (zh) |
FR (1) | FR2953520B1 (zh) |
HK (1) | HK1169984A1 (zh) |
IL (1) | IL220060A (zh) |
JO (1) | JO3098B1 (zh) |
MA (1) | MA33893B1 (zh) |
MX (1) | MX2012006421A (zh) |
MY (1) | MY157676A (zh) |
NZ (1) | NZ600368A (zh) |
SG (1) | SG181138A1 (zh) |
TW (1) | TWI481606B (zh) |
UY (1) | UY33079A (zh) |
WO (1) | WO2011067544A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2950345B1 (fr) * | 2009-09-18 | 2011-09-23 | Sanofi Aventis | Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique |
FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
AU2017364901A1 (en) | 2016-11-28 | 2019-06-13 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
WO2018098500A1 (en) * | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
CN110049975B (zh) * | 2016-12-08 | 2023-01-31 | 拜耳作物科学股份公司 | 制备5-(1-苯基-1h-吡唑-4-基)烟酰胺衍生物的方法 |
WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11866439B2 (en) | 2018-05-30 | 2024-01-09 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
CN111138325B (zh) * | 2019-12-20 | 2021-11-30 | 台州学院 | 一种(Z)-β-磺酰基烯胺类化合物的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200833329A (en) * | 2006-09-22 | 2008-08-16 | Sanofi Aventis | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
TW200944525A (en) * | 2008-03-21 | 2009-11-01 | Sanofi Aventis | Polysubstituted 2-heteroaryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139575A (ja) * | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
FR2928921B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
-
2009
- 2009-12-04 FR FR0958651A patent/FR2953520B1/fr not_active Expired - Fee Related
-
2010
- 2010-12-02 JO JOP/2010/0430A patent/JO3098B1/ar active
- 2010-12-03 BR BR112012013511A patent/BR112012013511A2/pt not_active IP Right Cessation
- 2010-12-03 MA MA35024A patent/MA33893B1/fr unknown
- 2010-12-03 JP JP2012541567A patent/JP5738310B2/ja not_active Expired - Fee Related
- 2010-12-03 SG SG2012039749A patent/SG181138A1/en unknown
- 2010-12-03 KR KR1020127017287A patent/KR101696959B1/ko active IP Right Grant
- 2010-12-03 CN CN201080062600.0A patent/CN102762559B/zh not_active Expired - Fee Related
- 2010-12-03 EP EP10801625.4A patent/EP2507238B1/fr not_active Not-in-force
- 2010-12-03 UY UY33079A patent/UY33079A/es not_active Application Discontinuation
- 2010-12-03 NZ NZ600368A patent/NZ600368A/en not_active IP Right Cessation
- 2010-12-03 WO PCT/FR2010/052605 patent/WO2011067544A1/fr active Application Filing
- 2010-12-03 MY MYPI2012002449A patent/MY157676A/en unknown
- 2010-12-03 AU AU2010326429A patent/AU2010326429B2/en not_active Ceased
- 2010-12-03 CA CA2782704A patent/CA2782704C/fr not_active Expired - Fee Related
- 2010-12-03 AR ARP100104462A patent/AR079250A1/es unknown
- 2010-12-03 EA EA201290520A patent/EA020652B1/ru not_active IP Right Cessation
- 2010-12-03 TW TW099142230A patent/TWI481606B/zh not_active IP Right Cessation
- 2010-12-03 MX MX2012006421A patent/MX2012006421A/es active IP Right Grant
- 2010-12-03 US US13/513,497 patent/US8680096B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 IL IL220060A patent/IL220060A/en not_active IP Right Cessation
- 2012-06-04 CO CO12093017A patent/CO6551713A2/es active IP Right Grant
- 2012-06-04 CL CL2012001461A patent/CL2012001461A1/es unknown
- 2012-10-22 HK HK12110468.8A patent/HK1169984A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200833329A (en) * | 2006-09-22 | 2008-08-16 | Sanofi Aventis | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
TW200944525A (en) * | 2008-03-21 | 2009-11-01 | Sanofi Aventis | Polysubstituted 2-heteroaryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2782704A1 (fr) | 2011-06-09 |
US20120245164A1 (en) | 2012-09-27 |
KR20120103672A (ko) | 2012-09-19 |
AU2010326429A1 (en) | 2012-06-21 |
MX2012006421A (es) | 2012-10-09 |
JP5738310B2 (ja) | 2015-06-24 |
MA33893B1 (fr) | 2013-01-02 |
WO2011067544A1 (fr) | 2011-06-09 |
JO3098B1 (ar) | 2017-03-15 |
EP2507238B1 (fr) | 2013-07-31 |
FR2953520B1 (fr) | 2011-11-25 |
EA201290520A1 (ru) | 2013-01-30 |
UY33079A (es) | 2011-06-01 |
JP2013512884A (ja) | 2013-04-18 |
CN102762559A (zh) | 2012-10-31 |
US8680096B2 (en) | 2014-03-25 |
SG181138A1 (en) | 2012-07-30 |
NZ600368A (en) | 2013-12-20 |
BR112012013511A2 (pt) | 2016-06-07 |
EA020652B1 (ru) | 2014-12-30 |
MY157676A (en) | 2016-07-15 |
KR101696959B1 (ko) | 2017-01-16 |
AR079250A1 (es) | 2012-01-04 |
CL2012001461A1 (es) | 2012-10-12 |
CA2782704C (fr) | 2018-01-02 |
HK1169984A1 (en) | 2013-02-15 |
IL220060A (en) | 2015-05-31 |
EP2507238A1 (fr) | 2012-10-10 |
CO6551713A2 (es) | 2012-10-31 |
FR2953520A1 (fr) | 2011-06-10 |
TW201129564A (en) | 2011-09-01 |
AU2010326429B2 (en) | 2016-07-14 |
CN102762559B (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI481606B (zh) | 二苯基吡唑并吡啶衍生物、其製備及其治療用途 | |
JP5336378B2 (ja) | 2−アリール−6−フェニルイミダゾ[1,2−α]ピリジン誘導体、これらの調製およびこれらの治療的使用 | |
JP5259587B2 (ja) | イミダゾ[1,2−a]ピリジン−2−カルボキサミド誘導体、その調製方法および治療におけるその使用 | |
MX2014013549A (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
CA2656045A1 (fr) | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique | |
TWI464169B (zh) | 5-苯基吡唑并吡啶衍生物,其製備及其治療應用 | |
JP2011508758A (ja) | N−フェニルイミダゾ[1,2−α]ピリジン−2−カルボキサミド誘導体、これらの調製およびこれらの治療用途 | |
TWI458728B (zh) | 炔系5-苯基吡唑并吡啶衍生物、其製備及其治療應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |